Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma

Table 2 Treatments of advanced hepatocellular carcinoma using combination therapies

Ref.	HCRN GI15-225[81]	NASIR-HCC[80]	SOLID[78]	Yu et al[96]	SORAMIC[70]
Publication date	2024	2022	2023	2023	2019
Combination tested	TARE + pembrolizumab	TARE + nivolumab	TARE + durvalumab	TARE + atezo-bev	TARE + sorafenib vs sorafenib
Sample size	27	42	24	10	216
ECOG performance status	0: 13 (48%), 1: 14 (52%)	0: 38 (90.5%), 1: 4 (9.5%)	0: 20 (83.3%), 1: 4 (16.7%)	0: 4 (40.0%), 1: 4 (40.0%), 2-3: 2 (20.0%)	NDA
Child-Pugh score	A: 26 (96.0%), B7: 1 (4.00%)	A5: 36 (85.7%), A6: 6 (14.3%)	A5: 21 (87.5%), A6: 3 (12.5%)	A: 8 (80.0%), B: 2 (20.0%)	A: 190 (88.0%), B: 26 (12.0%)
Median overall survival (months)	27.3	20.9	NDA	NDA	TARE + sorafenib: 12.1, sorafenib: 11.4
Median time to progression (months)	9.95	8.80	15.2	NDA	NDA
Objective response rate	36.0%	41.50%	83.3%	NDA	NDA
Median duration of response (months)	5.50	7.75	7.2	NDA	NDA
Median progression free survival (months)	9.95	9.0	6.9	NDA	NDA

atezo-bev: Atezolizumab-bevacizumab; TARE: Transarterial radioembolization; TACE: Transarterial chemoembolization; NDA: No data available; ECOG: Eastern Cooperative Oncology Group.